Application of atypical acetyl-lysine methyl mimetics in the development of selective inhibitors of the bromodomain-containing protein 7 (BRD7)/bromodomain-containing protein 9 (BRD9) bromodomains

Michael A. Clegg, Paul Bamborough, Chun-wa Chung, Peter D. Craggs, Laurue Gordon, Paola Grandi, Melanie Leveridge, Matthew Lindon, Gemma M. Liwicki, Anne-Marie Michon, Judit Molnar, Inmaculada Rioja, Peter E. Soden, Natalie H. Theodoulou, Thilo Werner, Nicholas C. O. Tomkinson, Rab K. Prinjha, Philip G. Humphreys

Research output: Contribution to journalArticle

Abstract

Non-BET bromodomain containing proteins have become attractive targets for the development of novel therapeutics targeting epigenetic pathways. To help facilitate the target validation of this class of proteins, structurally diverse small molecule ligands, and methodologies to produce selective inhibitors in a predictable fashion are in high demand. Herein we report the development and application of atypical acetyl-lysine (KAc) methyl mimetics to take advantage of the differential stability of conserved water molecules in the bromodomain binding side. Discovery of the n-butyl group as an atypical KAc methyl mimetic allowed generation of 31 (GSK6776) as a soluble, permeable and selective BRD7/9 inhibitor from a pyridazinone template. The n-butyl group was then used to enhance the bromodomain selectivity of an existing BRD9 inhibitor and to transform pan-bromodomain inhibitors into BRD7/9 selective compounds. Finally, a solvent exposed vector was defined from the pyridazinone template to enable bifunctional molecule synthesis and affinity enrichment chemoproteomic experiments were used to confirm several of the endogenous protein partners of BRD7 and BRD9 which form part of the chromatin remodelling PBAF and BAF complexes, respectively.
Original languageEnglish
Pages (from-to)5816-5840
Number of pages25
JournalJournal of Medicinal Chemistry
Volume63
Issue number11
Early online date15 May 2020
DOIs
Publication statusPublished - 11 Jun 2020

Keywords

  • bromodomain-containing proteins
  • therapeutics
  • n-butyl group
  • atypical KAc methyl mimetic

Fingerprint Dive into the research topics of 'Application of atypical acetyl-lysine methyl mimetics in the development of selective inhibitors of the bromodomain-containing protein 7 (BRD7)/bromodomain-containing protein 9 (BRD9) bromodomains'. Together they form a unique fingerprint.

  • Projects

    Cite this

    Clegg, M. A., Bamborough, P., Chung, C., Craggs, P. D., Gordon, L., Grandi, P., Leveridge, M., Lindon, M., Liwicki, G. M., Michon, A-M., Molnar, J., Rioja, I., Soden, P. E., Theodoulou, N. H., Werner, T., Tomkinson, N. C. O., Prinjha, R. K., & Humphreys, P. G. (2020). Application of atypical acetyl-lysine methyl mimetics in the development of selective inhibitors of the bromodomain-containing protein 7 (BRD7)/bromodomain-containing protein 9 (BRD9) bromodomains. Journal of Medicinal Chemistry, 63(11), 5816-5840. https://doi.org/10.1021/acs.jmedchem.0c00075